[PRESS RELEASE] – TORONTO, March 26, 2026 – Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that through its majority-owned subsidiary Santa Marta Golden Hemp SAS (SMGH), the company completed its first commercial export of CBG-dominant cannabis flower to Australia.
Over the past two years, Avicanna has invested in process development, infrastructure and quality systems to align SMGH’s operations with international regulatory expectations for active pharmaceutical ingredients (API) and raw materials. As a result, SMGH is positioned to produce consistent, standardized cannabis flower at a commercial scale, with a focus on cannabinoid-specific chemotypes, traceability and compliance with Good Agricultural and Collection Practices (GACP) and organic certification standards.
SMGH’s operational model incorporates several structural strengths relevant to the cultivation and production of cannabinoid API, including year-round cultivation enabled by equatorial conditions, controlled environmental parameters and established genetic portfolios registered in Colombia. These factors contribute toward supporting conditions for consistent production cycles, batch uniformity and cost efficiencies, which are essential for long-term participation in international medical cannabis markets.
This export also includes SMGH’s proprietary CBG cultivar, part of the company’s portfolio of registered varieties. With this shipment, SMGH has now supplied products into 21 international markets, and Avicanna products have reached 24 markets globally, reflecting the company’s experience navigating complex regulatory frameworks.
Avicanna carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
